Products: PathwayINTEL

PathwayINTEL identifies the functional biomarkers that predict the outcome a targeted therapy based on a profiling expression of transduction pathway protein expression and activation status within the patient’s  tumor.  With PathwayINTEl, physicians are able to select the most appropriate target therapy focused on the “driver” of tumor proliferation, survival and growth based on biomarker identification. Genomic based assays only inform on the potential for over expression and most proteomic based assays provide semi-quantitative confirmation of protein expression, but do not inform on whether the transduction pathway is activated and “driving” tumor growth.

The PathwayINTEL Platform gives researchers and physicians the power to:

• Profile the most susceptible cancers based on the mechanism of action of new target compounds
• Accurately quantify total protein expression and phosphoprotein (activated protein) levels
• Differentiate total protein expression and protein activation
• Identify appropriate targeted therapy and/or biologic therapy options based on functional pathway analysis
• Perform longitudinal disease monitoring
• Identify cancer adaptations or changes in biology following specific therapy

Foundational research on the CEER Assay, predecessor to PathwayINTEL is summarized by published articles below.

RESEARCH (click on PDF icons or file name):

pdf-iconLee, J., Kim, S., Kim, P., Liu, X., Lee, T., Kim, K. M., et al. (2013) A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers. PLoS ONE, 8(1): e54644. doi:10.1371/journal.pone.0054644

Verra, S., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman,B., Rodriguez, O., Guzman, M., Rodriguez, S., Gili, M., Russilo, M., Parra, J. L., Singh, S., Arribas, J., Rosen, N., & Baselga, J. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 30(22), 2547-57. doi: 10.1038/onc.2010.626

Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudsen, M., Muranen, T., Tao, J., Bosch Campos, A., Rodon, J., Ibrahim, Y. H., Serra, V., Rodrik-Outmezguine, V., Hazra, S., Singh, S., Kim, P., Quadt, C., Liu, M., Huang, A., Rosen, N., Engelman, J. A., Scaltriti, M., & Baselga, J. (2013). mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CAmutant breast cancer. Science Translational Medicine, 5(196), 196ra99. doi:10.1126/scitranslmed.3005747

pdf-iconJegg, A.M., Ward, T. M., Iorns, E., Hoe, N., Zhou, J., Liu, X., Singh, S., Landgraf, R., & Pegram, M.D. (2012). PI3K independent activation of mTORC1 as a target in lapatinibresistant ERBB2+breast cancer cells. Breast Cancer Research and Treatment, 136(3), 682-92. doi: 10.1007/s10549-012-2252-9

pdf-iconKim, P., Liu, X., Lee, T., Liu, L., Barham, R., Kirkland, R., Leesman, G., Kuller, A., Ybarrondo, B., Ng, S. C., Singh, S. (2011). Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Science, 9(1), 75. doi: 10.1186/1477-5956-9-75

pdf-iconLee, J., Jain, A., Kim, P., Lee, T., Kuller, A., Princen, F., In-GuDo, Kim, S.H., Park, J. O., Park, Y. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectalcancers independent of KRAS mutational status. PLoS One, 9(8): e103551. doi: 10.1371/journal.pone.0103551

Lee, J., Kim, S., Kim, P., Liu, X., Lee, T., Kim, K.M., Do, I.G., Park, J. O., Park, S.H., Jang, J., Hoe, N., Harvie, G., Kuller, A., Jain, A., Meyer, G., Leesman, G., Park, Y.S., Choi, M.G., Sohn, T.S., Bae, J. M., Lim, H. Y., Singh, S., & Kang, W.K. (2013). A novel proteomics based clinical diagnostics technology identifies heterogeneity inactivated signaling pathways in gastric cancers. PLoS ONE 8(1): e54644. doi:10.1371/journal.pone.0054644

Park, S., Langley, E., Sun, J. M., Lockton, S., Ahn, J. S., Jain, A., Park, K., Singh, S., Kim, P., & Ahn, M. J. (2015). Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in nonsmallcell lung cancer. Oncotarget, 6(31), 30929-38. doi: 10.18632/oncotarget.5131 Hua, C. G., Wang, S., Mayer, G., Chen, G., Leesman, G., Singh, S., & Beer, D. G. (2011).Signatures of drug sensitivity in nonsmall cell lung cancer. International Journal of Proteomics. doi:10.1155/2011/215496

Ward, T. M., Iorns, E., Liu, X., Hoe, N., Kim, P., Singh, S., Dean, S., Jegg, A. M., Gallas, M., Rodriguez, C., Lippman, M., Landgraf, R., & Pegram, M.D. (2013). Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion andorthotopic xeno graft formation, and is associated with loss of phosphorylated STAT5. Oncogene, 32(19), 2463-74. doi: 10.1038/onc.2012.256

Tao, J. J., Castel, P., Radosevic-Robin, N., Elkabets, M., Auricchio, N., Aceto, N., Weitsman, G., Barber, P., Vojnovic, B., Ellis, H., Morse, N., Viola-Villegas, N.T., Bosch, A., Juric, D., Hazra, S., Singh, S., Kim, P., Bergamaschi, A., Maheswaran, S., Ng, T., Penault-Llorca, F,. Lewis, J.S., Carey, L.A., Perou, C. M., Baselga, J., & Scaltriti, M. (2014). Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Science Signaling, 7(318), ra29. doi: 10.1126/scisignal.2005125